Drugs / RSVcps2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01968083 | Oct 2013 → May 2015 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01852266 | Oct 2013 → Jul 2015 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSVcps2 | “RSV cold-passage/stabilized 2 (RSVcps2) is a modification of a previously evaluated vaccine candidate in which 2 major attenuating mutations have been stabilized against deattenuation.” PMID 29509929 ↗ Apr 2018 |
| Known as | RSV cold-passage/stabilized 2 | “RSV cold-passage/stabilized 2 (RSVcps2) is a modification of a previously evaluated vaccine candidate in which 2 major attenuating mutations have been stabilized against deattenuation.” PMID 29509929 ↗ Apr 2018 |
| Modality | Vaccine | “RSV cold-passage/stabilized 2 (RSVcps2) is a modification of a previously evaluated vaccine candidate” PMID 29509929 ↗ Apr 2018 |
| Route | Intranasal | “administered as nose drops” NCT01852266 ↗ |